Edition:
India

Kalvista Pharmaceuticals Inc (KALV.OQ)

KALV.OQ on NASDAQ Stock Exchange Global Market

9.19USD
1:00am IST
Change (% chg)

$-0.80 (-8.01%)
Prev Close
$9.99
Open
$10.03
Day's High
$10.03
Day's Low
$9.16
Volume
21,917
Avg. Vol
31,221
52-wk High
$15.75
52-wk Low
$5.48

Latest Key Developments (Source: Significant Developments)

Kalvista Pharmaceuticals Reports Q2 Loss Per Share $0.50
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS REPORTS FISCAL SECOND QUARTER RESULTS.Q2 LOSS PER SHARE $0.50.Q2 REVENUE $1.1 MILLION VERSUS $200,000.  Full Article

Longwood Fund II reports 8.7 pct stake in Kalvista Pharmaceuticals ‍​
Saturday, 21 Oct 2017 

Oct 20 (Reuters) - Kalvista Pharmaceuticals Inc :Longwood Fund II Lp reports 8.7 pct stake in Kalvista Pharmaceuticals Inc as of Oct 12 - sec filing‍​.  Full Article

Kalvista Pharmaceuticals announces collaboration with Merck
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Kalvista Pharmaceuticals Inc :Kalvista Pharmaceuticals announces collaboration with Merck.Kalvista Pharmaceuticals - ‍investigational intravitreal DME candidate KVD001 phase 2 clinical trial still planned to initiate in 2017​.Kalvista Pharmaceuticals Inc - ‍Merck acquires 9.9% stake in Kalvista in private placement​.Kalvista Pharmaceuticals Inc - deal includes ‍$37 million upfront fee plus potential milestone payments and sales royalties​.Kalvista Pharmaceuticals Inc - ‍Kalvista also has granted to Merck a similar option to acquire investigational orally delivered molecules for DME​.Kalvista - ‍under deal terms, co granted to Merck rights including an option to acquire KVD001 through a period following completion of phase 2 trial.Kalvista - Co will fund, retain control over planned phase 2 clinical trial of KVD001, development of investigational oral DME compounds through phase 2​.Kalvista - eligible to get payments associated with exercise of options by Merck, achievement of milestones for each program potentially total $715 million​.  Full Article

Carbylan required to pay Kalvista termination fee of $3.0 mln if deal is terminated under certain circumstances
Wednesday, 15 Jun 2016 

Carbylan Therapeutics Inc :Upon termination of share purchase agreement under some circumstances, co may be required to pay kalvista a termination fee of $3.0 million.  Full Article

Carbylan Therapeutics and Kalvista pharmaceuticals enter into share purchase agreement
Wednesday, 15 Jun 2016 

Carbylan Therapeutics Inc : Carbylan Therapeutics Inc and Kalvista Pharmaceuticals Ltd Enter into share purchase agreement . Carbylan Therapeutics says have entered into share purchase agreement pursuant to which shareholders of Kalvista will become majority owners of co . Carbylan Therapeutics Inc says agreement if approved, Carbylan will be renamed Kalvista Pharmaceuticals Inc . Carbylan Therapeutics Inc says transaction has been unanimously approved by boards of directors of both companies . Carbylan Therapeutics Inc says upon closing of transaction, executive officers of Kalvista will assume their respective positions at combined company . Carbylan therapeutics inc says upon closing of transaction, executive officers of Kalvista will assume their respective positions at combined company, and executive officers of Carbylan will resign . Carbylan therapeutics inc says Kalvista shareholders will receive newly issued shares of common stock of Carbylan in connection with transaction . Carbylan therapeutics inc says upon closing of transaction, existing Kalvista equityholders are expected to own approximately 81% of combined company .Carbylan therapeutics inc says upon closing of transaction, Carbylan stockholders are expected to own approximately 19% of combined company.  Full Article

Carbylan Therapeutics reports top-line results from cor1.1 clinical trial of hydros-ta
Tuesday, 2 Feb 2016 

Carbylan Therapeutics Inc:Says given the comparable effectiveness at 26 weeks, cor1.1 did not meet its second primary endpoint.Hydros-ta was generally well tolerated with no treatment related serious adverse events.Hydros-ta met first primary endpoint,showed statistically significant improvement from baseline in womac a pain score versus hydros.  Full Article